U.S. markets open in 6 hours 37 minutes

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.12+0.54 (+9.68%)
At close: 4:00PM EST

Clovis Oncology, Inc.

5500 Flatiron Parkway
Suite 100
Boulder, CO 80301
United States
303 625 5000

Full Time Employees484

Key Executives

NameTitlePayExercisedYear Born
Mr. Patrick J. MahaffyCo-Founder, CEO, Pres & Exec. Director1.19MN/A1963
Dr. Gillian C. Ivers-ReadCo-Founder, Chief Regulatory Officer & Exec. VP of Technical Operations713.41kN/A1954
Mr. Daniel W. MuehlExec. VP & CFO691.45kN/A1964
Mr. Paul Edward GrossExec. VP, Gen. Counsel & Sec.697.38kN/A1965
Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPMExec. VP of Clinical, Preclinical Devel. & Pharmacovigilance and Chief Medical Officer760.03kN/A1968
Ms. Breanna BurkartVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Ann BozemanExec. VP of HRN/AN/AN/A
Ms. Anna SussmanVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Corporate Governance

Clovis Oncology, Inc.’s ISS Governance QualityScore as of December 1, 2020 is 7. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.